Answers are grounded in this paper and cite their sources.
Objective: To determine the prevalence, types and causes of drug-related problems (DRPs), and their distribution across chronic kidney disease (CKD) stages, prescribing patterns and polypharmacy among adults with non-dialysis CKD stages 3a–5 attending a tertiary-care nephrology outpatient department. Methods: This hospital-based cross-sectional study included 186 consecutively screened adults with non-dialysis CKD stages 3a–5 receiving at least three regular medicines in Erode, Tamil Nadu, India, from January to March 2024. DRPs were identified through structured medication review using renal-dosing references and Micromedex and classified using the Pharmaceutical Care Network Europe (PCNE) V9.1 system. Outcomes included DRP prevalence, DRPs per patient, PCNE problem and cause domains, study-specific severity, and medication burden across CKD stages. Results: Among 186 participants (mean age 58.4±12.7 y; 60.2% male), 138 (74.2%) had at least one DRP, with 342 DRPs identified (1.8±1.5 per patient). DRP prevalence increased from 58.3% in stage 3a to 96.0% in stage 5, while mean DRPs per patient increased from 1.2 to 3.0 (p<0.001). Treatment-safety problems accounted for 56.1% of DRPs. Dose selection (37.4%) and drug selection (35.1%) were the leading causes. Overall, 25.1% of DRPs were graded severe. Polypharmacy was common, with 85.5% receiving at least five medicines and 38.7% receiving ≥10 medicines. Conclusion: DRPs were frequent and increased across advanced CKD stages, particularly in the context of dose-selection problems and extensive polypharmacy. Structured pharmacist-led medication review and renal dose optimisation warrant prospective evaluation.
No takes yet. Share an insight, caveat, or question.
S. et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: